Koninklijke Philips (NYSE:PHG) Stock, Quote.Headers.trade-ideas

Koninklijke Philips

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (around 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal care products.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

AVXL

BMRC

CERO

CGTX

COMM

COUR

CPTN

CTRI

IART

ITRG

LGVN

LIPO

LUXH

MESO

NIPG

NISN

NLSP

NOVA

NUWE

OPTT

PGHL

PHIO

PYPD

RNLX

SERV

TIVC

TNDM

TSLA

TWOU

VERO

VTVT

VTYX

YIBO

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

xr:d:DAFpQHAbOpo:2,j:8265628418780073248,t:23072108

AEHR

CSTL

DXCM

OSCR

SHYF

ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday

OLYMPUS DIGITAL CAMERA

Earnings

Guidance

Eurozone

Health Care

General

Philips shares rose after Q2 2024 results exceeded expectations with €4.46 billion in sales and a 9% increase in order intake. Growth in Diagnosis &amp; Treatment, Connected Care, and Personal Health segments contributed to improved EBITA margins. CEO Roy Jakobs cited strong margins and cash flow improvements.

Philips Backs Annual Guidance On Higher Q2 Earnings Despite China Weakness

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips NV

Phil-Good Products Inc

BiomX Inc

PETS AT HOME GRP UNSP/ADR by Pets at Home Group PLC

Pets at Home Group PLC

PHARMING GROUP NV ORD by Pharming Group NV

Pharming Group

Philips Receives FDA Approval For Enhanced 160cm LumiGuide Guidewire, Marking 1000th Procedure Using Fiber Optic RealShape (FORS) Technology; First Use By Vascular Surgeon Carlos Timaran For Complex Aortic Repair

Biotech

AAPL

INSP

MASI

TEVA

VVOS

Apple Announces New Sleep Apnea Features On Apple Watch; Stocks With The Same Technology See Volume

<a href="https://www.globenewswire.com/Tracker?data=ybc5zkSdkFbkmoJagKp0ucFkdMRDvd4cAPDMX1SQi1xo-euNPoyvrA0GZSf0CZz9OO8hB5olxSnlFmaR_q3zMzof__sS7A5Xtjqru_KFxis=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)))), a global leader in health technology, and Isala hospital (Zwolle, The Netherlands) have renewed their long-term strategic partnership to enhance healthcare delivery through innovative and cost-effective solutions. This collaboration aims to ensure healthcare remains accessible, available, and affordable by leveraging Philips' advanced technology, data analytics, and AI. Focusing on the radiology and cardiology departments, it follows a successful collaboration that began in 2012. The new agreement will last for five years, with an option to extend for another five years.
Transforming healthcare with cutting-edge technology Isala will utilize Philips' technology to optimize processes and deliver more patient-centered care. Together, they will integrate new technologies into hospital operations and continuously improve products based on real-world data-driven feedback.
"Our focus is on maintaining accessible, available, and affordable care in a cost-effective way; the right technology plays a crucial role in this," said Jules de Vet, a member of the Board of Directors at Isala.
Sustainable and cost-effective medical systems replacement Isala will replace medical systems, such as MRI and CT scanners, through a flexible multi-year plan ensuring cost-effectiveness and sustainability. Continuous updates will keep systems state-of-the-art, extending their lifespan and benefiting both finances and the environment. Philips will provide essential medical imaging systems and support services to improve clinical adoption and streamline processes.
Enhancing clinical adoption of new technology "Hospitals face significant financial and personnel challenges in the coming years, and there is no single solution to these challenges," said Léon Kempeneers, Managing Director at Philips Benelux. "Together with Isala, we will work on enhancing the clinical adoption of new technologies such as AI, simplifying and enhancing healthcare providers' work."
This renewed partnership underscores the commitment of Philips and Isala to drive innovation and ensure sustainable, high-quality healthcare delivery.

Philips and Isala Hospital Renew Partnership, Aiming to Transform Healthcare with AI and Advanced Technology

&nbsp;<a href="https://www.globenewswire.com/Tracker?data=s6sZh72fLSzooVXAxzV2UlL1Fdw_RTKICZ2cFXGrx9LKHtkdTEbGABk4Eu06lD1TELykxo_WyPPSkaHQtRSiLBuIJk6u9IiQ_4tswZ9rcMs=" target="_blank">Royal Philips</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)))) today announced that it will repurchase shares for an amount of up to EUR 125 million to cover certain of its obligations arising from its long-term incentive plans. At the current share price, this represents a total of approximately 4.8 million shares.
The repurchases will be executed through a combination of forward transactions and open market purchases with a financial institution. Philips expects to take delivery of the forward share purchases in 2026. The open market purchases will be executed in&nbsp;Q3&nbsp;2024 by an intermediary to allow for share purchases during both open and closed periods. All repurchases will be executed in accordance with the EU Market Abuse Regulation and within the limits of the authorization granted by the company&#39;s General Meeting of Shareholders on May 7, 2024.

Buybacks

Philips To Buyback Shares For Up To €125M

Shares of Bank of Marin Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRC#NASDAQ">BMRC</a>) fell sharply during Monday's session after the company reported <a href="https://www.benzinga.com/quote/BMRC/earnings">worse-than-expected quarterly earnings.</a>
Bank of Marin reported quarterly earnings of 6 cents per share which missed the analyst consensus estimate of 18 cents per share. The company reported quarterly sales of $22.47 million which missed the analyst consensus estimate of $23.39 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Marin Bancorp shares dipped 10.8% to $19.92 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares climbed 128% to $2.8535.</li>
<li>Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares climbed 117.8% to $0.9039 after the company announced it commenced its Phase 2a trial for LP-310 in Oral Lichen Planus.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) gained 61.6% to $4.75 after jumping around 56% on Friday.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) jumped 38% to $0.2644 after the company announced a merger in which Kadimastem will become a wholly owned subsidiary of NLS.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares gained 37.8% to $0.6232 after gaining 11% on Friday.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) gained 34.4% to $12.25.</li>
<li>Nisun International Enterprise Development Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) jumped 26.8% to $14.76.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) jumped 24.2% to $0.4366.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) rose 23.5% to $2.9860.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) jumped 22.5% to $0.7936 after the company received a medical device license from Health Canada to market its Venus Bliss MAX system.</li>
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) gained 21.3% to $2.8862. Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and announced a price target of $17.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares gained 19.8% to $4.1246 after the company disclosed study results from CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer&#8217;s disease.</li>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 19.3% to $0.5021. BurgerFi shares jumped 97% on Friday after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) climbed 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) rose 18.4% to $4.19.</li>
<li>Cepton, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) jumped 18.4% to $2.9950 after the company announced it will be acquired by Koito for $3.17 per share in cash.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) gained 16.1% to $15.35.</li>
<li>ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) jumped 13.7% to $79.76 after the company reported better-than-expected second quarter financial results.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rose 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) gained 9.5% to $5.09.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) rose 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) gained 6.4% to $7.18. Anavex Life Sciences presented comprehensive results from the Phase IIb/III study showing that blarcamesine, once daily orally, significantly slowed clinical decline in people with early Alzheimer&#8217;s disease.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cognition Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) fell 34% to $1.5650 after the company reported Phase 2 results for Alzheimer&#8217;s drug.</li>
<li>vTv Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) shares dipped 31.4% to $14.55 after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 28.6% to $0.1830 after gaining 6% on Friday.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) fell 26.4% to $14.90 following downbeat quarterly results.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) dipped 24.4% to $2.23. The company released results from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn's disease, a type of inflammatory bowel disease that irritates and causes swelling in digestive tract.</li>
<li>LuxUrban Hotels Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) shares fell 19.6% to $0.1536 after the company priced its $1.74 million public offering of 11,573,333 common shares at 15 cents per share.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) declined 18.5% to $8.84.</li>
<li>Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>) fell 17.5% to $0.2544.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) shares fell 17% to $1.5243.</li>
<li>Integra Resources Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#NYSE">ITRG</a>) fell 16.6% to $0.8999. Integra Resources and Florida Canyon Gold entered into a definitive arrangement agreement, whereby Integra has agreed to acquire all of the issued and outstanding shares of FCGI pursuant to a court-approved plan of arrangement.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 16.6% to $3.3616. Phio Pharmaceuticals recently announced exercise of warrants for $3.1 million gross proceeds.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) dipped 13.9% to $27.05 after the company lowered its FY24 guidance below estimates.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 12.8% to $14.01.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) fell 10.5% to $9.60.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) declined 10% to $7.24. Truist Securities analyst Jordan Levy maintained Sunnova Energy Intl with a Buy and raised the price target from $9 to $10.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $6.85. Mesoblast, last week, announced that the FDA accepted its Biologics License Application resubmission for Ryoncil in the treatment of children with steroid-refractory acute graft versus host disease.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) fell 6.3% to $139.61 after HSBC downgraded the stock from Hold to Reduce.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) fell 6.3% to $37.53.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40011559/wall-streets-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Monday.
Shares of ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/40010835/on-semiconductor-q2-earnings-revenue-and-eps-beat-ceo-highlights-automotive-gains-strong-q3-outlook">second quarter financial results</a>.
ON Semiconductor reported a fiscal second-quarter 2024 revenue decline of 17.2% year-on-year to $1.74 billion, beating the analyst consensus estimate of $1.73 billion. The adjusted EPS of 96 cents beat the analyst consensus estimate of 92 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
ON Semiconductor said it expects third-quarter adjusted revenue of $1.70 billion – $1.80 billion, versus the consensus of $1.73 billion. The company sees adjusted EPS of 91 cents to $1.03 versus the consensus of 92 cents.
ON Semiconductor shares jumped 13.7% to $79.76 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) shares jumped 34.4% to $12.25.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) shares gained 23.5% to $2.9860.</li>
<li>Oil States International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIS#NYSE">OIS</a>) shares jumped 18.8% to $5.63 after the company reported better-than-expected second-quarter financial results.</li>
<li>CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) gained 17.2% to $2.25 after reporting preliminary second quarter results.</li>
<li>Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) rose 16.1% to $15.35.</li>
<li>Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) climbed 13.1% to $29.14 after the company reported better-than-expected second quarter earnings.</li>
<li>The Shyft Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) gained 11.2% to $15.33. DA Davidson analyst Michael Shlisky upgraded Shyft Group from Neutral to Buy and raised the price target from $12 to $18.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) gained 8.5% to $18.48. ZIM Integrated Shipping Services will release its second quarter financial results on Monday, Aug. 19.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) jumped 8.1% to $17.09.</li>
<li>Aehr Test Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) gained 6.6% to $19.06.</li>
<li>Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) gained 6.4% to $22.40.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) rose 6% to $67.97.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) jumped 5.7% to $13.51.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 5.6% to $232.15. Morgan Stanley analyst Adam Jonas reiterated Tesla with an Overweight and maintained a $310 price target.</li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) gained 4.5% to $27.65. On July 18, Morgan Stanley downgraded the stock from Equal-Weight to Underweight and lowered its price target from $24 to $18.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40011827/more-than-4m-bet-on-appian-check-out-these-3-stocks-insiders-are-buying">More Than $4M Bet On Appian? Check Out These 3 Stocks Insiders Are Buying</a></li>
</ul>

LGVN: &nbsp;49% &#x7C; <a href="https://www.benzinga.com//node/40002230">Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease; Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk Profile</a>
&nbsp;
PHG: 11% &#x7C; <a href="https://www.benzinga.com//node/40003536">Koninklijke Philips Q2 2024 Adj EPS €0.30 Beats €0.25 Estimate, Sales €4.462B Beat €4.430B Estimate</a>
&nbsp;
LIPO: &nbsp;204% &#x7C; <a href="https://www.benzinga.com//node/40005335">Lipella Pharmaceuticals Commences Phase 2a Trial For LP-310 In Oral Lichen Planus, Enrolls First Patients</a>

Market-Moving News for July 29th

Koninklijke Philips N.V (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) stock is trading higher on Monday after the company released its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40003525/philips-delivers-strong-order-intake-growth-in-the-second-quarter-margin-improvement-and-sales-gro" rel="noreferrer noopener">second-quarter&nbsp;2024 financial results</a>.
The company&#8217;s second-quarter sales reached 4.46 billion euros ($4.83 billion), beating the consensus of 4.43 billion euros.
Comparable sales increased by 2%, driven by growth across all segments. The decline in China partly offsets growth in mature and growth geographies.
Comparable order intake grew 9% in the quarter and 3% in the first half of 2024, reflecting quarterly unevenness in the order-intake pattern.
Related: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/05/38824734/philips-sues-soclean-alleging-ozone-exposure-risks-over-injuries-related-to-breathing-devices" rel="noreferrer noopener">Philips Sues SoClean Alleging Ozone Exposure Risks Over Injuries Related To Breathing Devices</a>.
China remains a fundamentally attractive growth market with strong underlying demand while the government&#8217;s anti-corruption measures continue to impact short-term hospital order lead times.
The company reported an adjusted EPS of 0.30 euros, up from 0.27 euros a year ago.
&#8220;I am encouraged by our return to order intake growth this quarter, primarily driven by North America. Within a challenging macro environment, we achieved strong margin improvement, supported by our productivity program, solid operational cashflow due to improved working capital management, and comparable sales growth in line with our plan,&#8221; CEO Roy Jakobs <a target="_blank" href="https://www.philips.com/a-w/about/news/archive/corpcomms/news/press/2024/philips-second-quarter-results-2024.html" rel="noreferrer noopener">said</a> in a statement.
Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-07-29/philips-new-orders-rise-after-sleep-apnea-turbulence-abates" rel="noreferrer noopener">notes</a> that the company is regaining investors&#8217; confidence after a lower-than-expected settlement on U.S. claims linked to faulty sleep <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38488808/philips-reaches-1-1b-settlement-on-us-sleep-apnea-devices-claims-backs-annual-guidance" rel="noreferrer noopener">apnea devices in late April</a>.
Diagnosis &amp; Treatment&nbsp;comparable sales increased by 4%, with growth across Image Guided Therapy and Precision Diagnosis. Adjusted EBITA margin improved to 12.2%, mainly driven by improved sales, pricing and productivity measures.
Connected Care&nbsp;comparable sales increased 2%, driven by strong growth in Enterprise Informatics, while Monitoring comparable sales growth was flat. Adjusted EBITA margin improved to 8.8%, mainly driven by productivity measures and pricing.
Personal Health&nbsp;comparable sales increased by 2% globally, driven by sales growth outside of China. Adjusted EBITA margin improved to 16.9%, mainly driven by operational improvements and productivity measures.
The adjusted EBITDA margin increased to 11.1% from 10.1% last year, with improvement across all businesses.
Guidance: Looking ahead to fiscal 2024, Philips expects 3%-5% comparable sales growth, an adjusted EBITA margin of 11%-11.5%, and free cash flow of €0.9 billion to €1.1 billion.
Dutch health-technology company reiterated its confidence in delivering the 2025 plan, acknowledging that uncertainties remain.
The outlook excludes the potential impact of the ongoing Philips Respironics-related legal proceedings, including the U.S. Department of Justice investigation.
Price Action: PHG stock is up 10.1% at $28.36 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/06/39505577/billionaire-agnelli-is-philips-largest-shareholder-now-whats-going-on" target="_blank" rel="noreferrer noopener">Billionaire Agnelli Is Philips&#8217; Largest Shareholder Now &#8211; What&#8217;s Going On?</a></li>
</ul>
Photo via Wikimedia Commons

Index futures trading indicates cautious optimism as traders anticipate a busy week, with a slew of earnings reports, the two-day Federal Open Market Committee meeting starting Tuesday, and Friday&#8217;s non-farm payrolls report. Traders may look to take a position in <a href="https://www.benzinga.com/news/earnings/24/07/39993819/tech-stocks-slide-on-earnings-us-economy-flexes-muscles-small-cap-rally-continues-this-week-in-the-">stocks that have pulled back during the recent market retreat </a>ahead of what they perceive to be a strong reporting season.
Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are among the key tech earnings due this week, potentially setting the tempo for the market.

<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.61%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.41%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.39%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.60%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) moved up 0.38% to $546.50, and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) gained 0.57% to $465.63, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Week:
U.S. stocks meandered to a mixed close in the week ended July 26, with the Nasdaq Composite and the S&amp;P 500 declining for a second straight week amid some disappointing tech earnings. The blue-chip Dow Jones Industrial Average rose moderately, while the Russell 2,000 Index advanced notably for the week. 
The major averages started the week on a positive note but negative reactions to earnings from the likes of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) pushed the tech-heavy Nasdaq Composite and the S&amp;P 500 Index lower for the next three sessions. With the Fed&#8217;s favorite inflation gauge released Friday coming in tamer than expected, the indices rebounded and yet ended the week notably lower. 
The small-cap rally continued unabated as rate-cut bets prompted investors to bid up these stocks. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Week&#8217;s Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.08%</td>
<td>17,357.88</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>-0.83%</td>
<td>5,459.10</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+0.75%</td>
<td>40,589.34</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+3.47%</td>
<td>2,260.07</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
LPL Financial Chief Global Strategist Quincy Krosby sees the small-cap rally as more than a function of mere expectations that the Fed will cut interest rates. In a note released Friday, the strategist said attractive valuations have also underpinned sentiment. He pointed to another narrative. &#8220;There's also a strong narrative that the ongoing de-globalization could serve as a fundamental catalyst for small and mid-cap names,&#8221; he said.
Also, small-caps continue to see inflows despite the political ebb and flow, and mixed economic signals, and this according to Krosby is an indication that &#8220;they see a solid economic backdrop coupled with lower interest rates.&#8221; &#8220;The small caps – with a higher risk profile than the S&amp;P 500 – is known to sell off quickly when they perceive a material change in direction,&#8221; he added.
Yardeni Research&#8217;s President and Chief Investment Strategist Ed Yardeni said the market will likely churn around the current levels under the July 16 high (closing) of 5667.20 through the presidential election before <a href="https://www.benzinga.com/24/07/40004604/s-p-500-likely-to-end-year-strong-but-election-uncertainty-may-cause-short-term-volatility-says-yard">pushing toward new highs by the end of the year. </a>
Upcoming Economic Data:
The Fed meeting scheduled for July 30-31 and the July non-farm payrolls report due Friday are the key Main Street catalysts for the week. ADP&#8217;s private payrolls data for July released Wednesday could also evince some interest. Traders may also focus on S&amp;P Global&#8217;s final July manufacturing activity data, the Institute for Supply Management&#8217;s manufacturing purchasing managers&#8217; index for July and a regional business barometer.
Twin May house prices data, the weekly jobless claims data, the June Job Openings and Labor Turnover survey results, the second-quarter employment cost index, and the June pending home sales as well as the June factory goods orders data round up the economic events of the week.
On Monday, the Dallas Fed will release its manufacturing business index for July at 10:30 a.m. EDT.
The Treasury will auction three- and six-month notes at 11:30 a.m. EDT.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Stocks In Focus:
<ul>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rose nearly 5% in premarket trading, as the stock lock-stepped with cryptocurrencies.</li>
<li>U.S.-listed shares of Dutch consumer-electronics giant Koninklijke Philips N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) rallied over 10% following its earnings announcement.</li>
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) fell over 6% on an adverse legal ruling.</li>
<li>McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) and ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) are among the key companies due to <a href="https://www.benzinga.com/calendars/earnings">release their earnings reports ahead of the market opening.</a></li>
<li>Those reporting after the close include F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>), Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>), Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>), Chesapeake Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHK#NASDAQ">CHK</a>), Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) and Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>).</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures have started the week on a weak note, as they pulled back below the $77-a-barrel mark and gold futures also fell modestly. The yield on the 10-year Treasury note fell 4.1 points to 4.158%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) climbed over 3% and approached the $70K psychological barrier.
Most Asian markets rallied, led by the Japanese and Hong Kong markets, as regional investors cheered the rebound of U.S. stocks last Friday. The Japanese also awaited the Bank of Japan&#8217;s rate decision due this week. The Chinese market ended with a more muted gain, while the New Zealand market bucked the trend and ended modestly lower.
European stocks rallied sharply as traders digested positive earnings reports from the region.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40006542/apple-amazon-microsoft-meta-lead-the-charge-as-investors-bank-on-tech-cheer-for-ral">Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally&#8217;s Reacceleration: Week Ahead In Earnings</a></li>
</ul>
Image via Shutterstock.

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

$BTC

AMZN

COIN

FFIV

GOOG

GOOGL

LSCC

MSFT

RMBS

SANM

TLRY

US Stocks Look To Extend Gains Ahead Of Key Tech Earnings, FOMC Meeting: Analyst Says This 'Could Serve As A Fundamental Catalyst For Small And Mid-Cap'

WIIM

Koninklijke Philips shares are trading higher after the company reported better-than-expected Q2 earnings.

Outlook 
Philips reiterates its confidence in delivering the 2025 plan, acknowledging that uncertainties remain. For the full year 2024, Philips continues to expect 3-5% comparable sales growth, an Adjusted EBITA margin of 11-11.5%, and free cash flow of EUR 0.9-1.1 billion. 
The outlook excludes the potential impact of the ongoing Philips Respironics-related legal proceedings, including the investigation by the US Department of Justice

Koninklijke Philips Reiterates 2024 Outlook: Continues To Expect 3-5% Comparable Sales Growth And Adjusted EBITA Margin Of 11-11.5%; Sees Free Cash Flow Of EUR 0.9B-1.1B

Koninklijke Philips Q2 Comparable Order Intake Grew 9% And 3% In H1 2024

Koninklijke Philips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) reported quarterly earnings of €0.30 per share which beat the analyst consensus estimate of €0.25 by 20 percent. This is a 11.11 percent increase over earnings of €0.27 per share from the same period last year. The company reported quarterly sales of €4.462 billion which beat the analyst consensus estimate of €4.430 billion by 0.72 percent. This is a 8.38 percent decrease over sales of €4.870 billion the same period last year.

Earnings Beats

Koninklijke Philips Q2 2024 Adj EPS €0.30 Beats €0.25 Estimate, Sales €4.462B Beat €4.430B Estimate

Patient monitoring platform to deliver tools and time to help patients across 40+ care sites
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.philips.com%2Fnewscenter&amp;esheet=54095413&amp;newsitemid=20240716028105&amp;lan=en-US&amp;anchor=Royal+Philips&amp;index=1&amp;md5=29a5034e7c330c4e31500c1c431a563f">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)))) a global leader in health technology and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbsmhealth.org%2F&amp;esheet=54095413&amp;newsitemid=20240716028105&amp;lan=en-US&amp;anchor=Bon+Secours+Mercy+Health&amp;index=2&amp;md5=a74db2bc743760d9d051eb499546c274">Bon Secours Mercy Health</a> (BSMH), one of the nation's largest Catholic health systems, today announced a multi-year strategic collaboration for patient monitoring. Putting BSMH clinicians in control, the collaboration will reduce the digital burden on staff and give them more time to spend with patients.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240716028105/en/">https://www.businesswire.com/news/home/20240716028105/en/</a>
The partnership provides access to the latest Philips monitoring innovations, including a scalable patient monitoring platform that integrates patient data and provides vital insights. It will standardize patient monitoring for BSMH's 49 hospitals, reducing costs through a predictable payment model and enabling further reinvestment in innovation.
"This collaboration is part of our commitment to drive improved healthcare quality while reducing costs and addressing healthcare issues facing entire communities," said Jodi Pahl, Chief Nursing Officer for workforce experience and nursing outcomes, Bon Secours Mercy Health. "This 10-year journey will bring innovations that will transform care delivery."

Bon Secours Mercy Health And Philips Sign Multi-Year Strategic Collaboration For Patient Monitoring

FDA Says Philips To Correct Affected OLA+ Ventilator With Software Patch To Address Ventilation Inoperative Alarm Issue

Royal Philips NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">higher on Wednesday</a>. Italy's famous Agnelli family has increased its investment in Philips, showcasing a robust vote of confidence in the Dutch firm known for its medical devices.
Through Exor NV, the family's holding company, the Agnellis now controls <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/313216/000119312524167907/d826824dsc13da.htm" rel="noreferrer noopener">17.51% of Philips</a>, enhancing their position as the company's largest shareholder, an increase from <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/313216/000119312524140761/d841370dsc13da.htm" rel="noreferrer noopener">16.1% recorded</a> in May.
This expansion in their stake is indicative of growing trust in Philips' market prospects and management following the recent resolution of legal issues in the U.S., reported <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-06-26/billionaire-agnellis-boost-stake-in-philips-to-4-19-billion?srnd=technology-vp&amp;sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a>.
Philips reached a $1.1 billion settlement in the U.S. related to the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38488808/philips-reaches-1-1b-settlement-on-us-sleep-apnea-devices-claims-backs-annual-guidance" rel="noreferrer noopener">recall of its Respironics ventilators</a>.
Originally founding the automotive giant Fiat, the Agnelli family has diversified Exor's interests into healthcare, technology, financial services, and luxury goods.
Their initial purchase of a 15% stake in Philips last year marked a strategic pivot towards these industries.
The family's recent acquisition involved 19.5 million additional Philips shares, valued at approximately $514 million (481 million euros).
This brings Exor's total investment in Philips to about 3.3 billion euros, solidifying their commitment to the healthcare technology provider.
Philips&nbsp;reported first-quarter sales of $4.49 billion, beating the consensus estimate of $4.46 billion and an adjusted EPS of $0.28, <a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38488808/philips-reaches-1-1b-settlement-on-us-sleep-apnea-devices-claims-backs-annual-guidance" rel="noreferrer noopener">which was&nbsp;in line with the consensus</a>.
Following this announcement, Philips' stock experienced a 3.3% rise in Amsterdam, reflecting a positive market reaction.
Philips stock has gained more than 27% in the last 12 months. Investors can gain exposure to the stock via Dimensional International Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIV#NYSE">DFIV</a>) and Avantis International Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVDE#NYSE">AVDE</a>).
Price Action: PHG shares are trading higher by 0.63% at $25.60 at the last check on Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Wikimedia Commons

Media

AVDE

DFIV

Billionaire Agnelli Is Philips' Largest Shareholder Now - What's Going On?

<ul>
<li>Intuitive motorization for greater control and high-power (25 kW [1]) for state-of-the-art image quality supports complex vascular needs and a full range of clinical procedures</li>
<li>Automated workflows contribute to greater flexibility and independence for clinicians, providing more time to focus on achieving the best possible outcomes for patients</li>
</ul>
Amsterdam, the Netherlands – <a href="https://www.globenewswire.com/Tracker?data=K_QA91aSEzPIjzWv6dk3ljRZtd40lTsQwbOqMiaMXSAPMYJ5FQMCpjQz0bS897NEKbWlML2UXMVnskPdUQD7F7-Jcid3UnCh7A39X39SPyY=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)))), a global leader in health technology, today announced the launch of Philips Image Guided Therapy Mobile C-arm System 9000 – <a href="https://www.globenewswire.com/Tracker?data=WllWImnDYdPstSZOsYkZcrj1nbgYEvCfzER_jLjYU-mTocvpykuR99Y0qOYQLGdij5ZiwtgL5fKv8Pvt25ItgNqmHWE7rCe_VGi9UIt6z1HTSwbXqoKBm5E7FWXs6u9jq26Ni_eNgDjiUXE1zWQELw==">Zenition 90 Motorized</a>, designed to help clinicians deliver high-quality care to more patients. Philips is partnering with its customers to improve productivity. The new mobile C-arm with expanded capabilities is designed to meet complex vascular needs, but also a range of clinical procedures such as cardiac interventions, pain management and urology. Philips will be showcasing its newly introduced mobile C-arm at the <a href="https://www.globenewswire.com/Tracker?data=1_6JPF_wehq2HwPUnvJbEb5NJGO0l5AR4l0FdVzJXK1IuIglua4XI5CReq7KHlr1osTUoFc-BE6xaUVqTf4VrLABSI5T1WyE9sBcnlBbF7re8thYuyrhzloIgs1JBjNJCYVu2awBGuXwXXHRJ3eBRUnoHAw0I8JF30g0vAVYjbOb91pTt04JOpiUSufTPr2sRqP-pD7bLtp8EcLh5m0b3BoYF49VOuBRefXusqTN40gCqZiqwfkeLtG11RlVwDiF_VBiX29BlV9TaneSyMHzkMg7sv5qUwZ0PP9KH2DNTPfF3XAsHY_ySJqE-jlabJVZ5LMJzr-2iNzV8_AiIl4qEiUkZ2998R9Thg7YkhejW1pLX6oP3Ih0AkBYHOS9kkqwfDmNH0Ta05Ms0Rx2ZGVTk3BEF3N6E9k_4xf9Th3iqloIXAlGlQ0h7fKaKTb2r19R8nqHfDY36emG6z3q0YhqBDrPejS_vGeGAXZw3gRsy5JVhktPdncc9VAQVMYI3yVdNgUS8iEJcUMrmG-ANCBkHExbMs5CSX6UKCVG-9FidqYhi7R1AxTPAAgYN84-4WMeomXXvNVep3wiox2lswUKDkqNtcXoM5QqzKIHXdjQF2ULSjRaFsDW5N9kOLEhQPRr">2024 Society for Vascular Surgery Annual Meeting</a>, June 19-22, in Chicago.

Philips Zenition 90 Motorized Receives FDA 510(k) Clearance To Help Clinicians Deliver High Quality Care With A High-Powered And Fast Motorized Mobile C-Arm

Sanger Heart &amp; Vascular Institute, Atrium Health, treated the first patient with the new implantable medical device following FDA premarket approval
Amsterdam, the Netherlands – <a href="https://www.globenewswire.com/Tracker?data=EI3tJBrs1VRznbOHKjIXuLASrW1Oea0KCbwjNMayolLu2aaFZCIz2CMELYW37gYPVyc-7KWNaI7_KqhI6cW_8M51-RmVaPvC8O7fPRVJHHw=">Royal Philips</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHG#NYSE">PHG</a>, AEX: PHIA)))), a global leader in health technology, today announced the first implant of the Duo Venous Stent System, an implantable medical device indicated to treat symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI), following premarket approval (PMA) from the U.S. Food and Drug Association (FDA).

Philips Launches Duo Venous Stent System For Treatment Of Symptomatic Venous Outflow Obstruction In Patients With CVI

Royal Philips Announced The Successful Nationwide Rollout Of Its Ambulatory Cardiac Monitoring Service In Spain Using Its Unique Wearable ePatch Paired With Its AI-driven Cardiologs Analytics Platform

Three studies demonstrate how Philips MCOT wearable ambulatory monitoring ECG and proprietary AI&nbsp;models applied to ECG digital biomarkers can help to&nbsp;improve diagnosis, reduce readmissions, and lower costs

Tech

Philips Presents Study Results At Heart Rhythm Annual Meeting Showcasing Benefits Of Its AI-Powered Cardiac Monitoring Solution

Kepler Capital analyst Oliver Reinberg maintained a Buy rating on Koninklijke Philips N.V. (0LNG – Research Report) on August 30 and set a price ta...

Kepler Capital  Sticks to Its Buy Rating for Koninklijke Philips N.V. (0LNG)

Koninklijke Philips (PHG) has released an update. Royal Philips has disclosed the repurchase of 68,408 of its own shares at an average price of EUR...

Philips Executes Share Repurchase for Incentive Plans

Inspire Medical gains on GLP-1 prospects

In a report released on September 5, Oliver Reinberg from Kepler Capital maintained a Buy rating on Koninklijke Philips N.V. (0LNG – Research Repor...

In a report released on September 12, Oliver Reinberg from Kepler Capital maintained a Buy rating on Koninklijke Philips N.V. (0LNG – Research Repo...

Kepler Capital  Reaffirms Their Buy Rating on Koninklijke Philips N.V. (0LNG)

Philips wins FDA approval for new LumiGuide endovascular navigation wire

In a report released today, David Adlington from J.P. Morgan maintained a Hold rating on Koninklijke Philips N.V. (0LNG – Research Report), with a ...

Koninklijke Philips N.V. (0LNG) Receives a Hold from J.P. Morgan

Jefferies analyst Julien Dormois maintained a Sell rating on Koninklijke Philips N.V. (0LNG – Research Report) today and set a price target of €23....

Jefferies Reaffirms Their Sell Rating on Koninklijke Philips N.V. (0LNG)

Vivos surges on FDA nod for pediatric sleep apnea device

In a report released on September 18, Oliver Reinberg from Kepler Capital maintained a Buy rating on Koninklijke Philips N.V. (0LNG – Research Repo...

Kepler Capital  Remains a Buy on Koninklijke Philips N.V. (0LNG)

RYLPF

Press Releases

Philips appoints Ling Liu as Chief Region Leader of Philips Greater China

Bon Secours Mercy Health and Philips Sign Multi-Year Strategic Collaboration

Bon Secours Mercy Health and Philips sign multi-year strategic collaboration

Philips delivers strong order intake growth in the second quarter, margin improvement and sales growth; reiterates full-year outlook

Philips to repurchase shares for up to EUR 125 million to cover long-term incentive plans

Philips and Dutch Isala Hospital renew long-term partnership focused on innovation and affordable, sustainable healthcare

Carilion Clinic Further Expands Quality Cardiac Care Access with Latest Philips Innovations at Region's Premier Cardiovascular Institute at Crystal Spring Tower in Virginia

Carilion Clinic further expands quality cardiac care access with latest Philips innovations at new regional cardiovascular institute in Virginia, US

World Stroke Organization and Philips call for action to expand access to life-saving stroke care

Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Koninklijke Philips

Koninklijke Philips (PHG) Forecast

Koninklijke Philips (NYSE:PHG) Stock, Quote.Headers.trade-ideas